FDA Drug Safety Communication: Connection problems involving certain needleless pre-filled glass syringes containing adenosine and amiodarone
Featured In: Regulatory News
By Federal Drug Administration
Friday, May 6, 2024
Get daily Bioscience Technology industry top stories and headlines - Sign up now!
FDA Drug Safety Communication: Connection
problems involving certain needleless pre-filled glass syringes
containing adenosine and amiodarone
Safety
Announcement
Additional
Information for Healthcare Professionals
Data
Summary
List of
Affected Adenosine and Amiodarone Products
IV Access
Systems Known to be Incompatible with Adenosine and Amiodarone
Pre-filled Glass Syringes
References
Safety Announcement
[05-06-2024] The U.S. Food and Drug Administration (FDA)
is alerting the healthcare community about syringe connection
problems when certain needleless glass syringes containing the
cardiac drugs adenosine and amiodarone are used with particular
types of intravenous (IV) access systems. The adenosine and
amiodarone needleless pre-filled glass syringes and the IV access
systems known to be affected by this announcement are listed below.
Facts about adenosine
and amiodarone
|
SOURCE